Founder and CEO
About US
Why we exist.
suPARbio is a company that measures chronic inflammation through a blood test.
Origin
A founder story, grounded in evidence.
suPARbio was formed by Matt Wiggins, an American healthcare entrepreneur and investor - who has dealt since childhood with health issues caused by chronic inflammation, known as Meniere’s disease. His research led him to Denmark, where Danish scientists have studied chronic inflammation for more than 25 years. The team, lead by Dr. Jesper Eugen-Olsen discovered that a protein called soluble urokinase Plasminogen Activator Receptor (suPAR) is a stable biomarker for chronic inflammation.
suPARbio is grateful to have an exclusive United States distribution agreement for the soluble urokinase Plasminogen Activator Receptor (suPAR) biomarker with ViroGates A/S, a NASDAQ listed company based in Denmark.
suPARbio looks forward to making available 25 years of pioneering work from Danish bioscientist Dr. Jesper Eugen-Olsen, and his band of merry pranksters at ViroGates in Birkerod, Denmark. The team at ViroGates A/S is responsible for discovering suPAR’s prognostic significance in the 1990s and advancing the peer reviewed & published research on suPAR.
Today, Virogates A/S holds a significant patent portfolio around all aspects of the suPAR biomarker, including its clinical use worldwide. The team at suPARbio believes that individuals, physicians and anyone interested in population health management - should be paying attention to the insights around "biological risk" from suPAR testing.
People
People behind the work.
Danish bioscientist
Dr. Jesper Eugen-Olsen
Jakob Knudsen, CEO of ViroGates, says:
“We are happy to start a collaboration with SuPARbio to target the United States market. Knowledge of an individual’s suPAR score is an excellent marker for those interested in a healthier lifestyle. We are also very happy to welcome Remedy Ventures (Matt Wiggins) as one of our sizable investors in our cap table. We believe that the combination of a distribution agreement and direct investment is a strong signal that suPARbio and Remedy are committed to this big opportunity, and we look forward to supporting the efforts in the US with data from our research and development efforts worldwide over the past 20 years.”
Matt Wiggins, Managing Partner of suPARbio, says:
“Unmanaged chronic inflammation in individuals - being labelled 'inflammaging' by some scientists - leads to costs in the US healthcare system, so I believe many cost containment and population health management strategies could eventually include proactive monitoring of suPAR levels. Knowledge is power, and in the future it's possible health insurance companies could offer the test as a benefit to their members, since health plan benefit designs often reimburse for the type of lifestyle interventions and treatments that keep individuals’ chronic inflammation under control and lower their suPAR scores. For now, this distribution partnership enables the rapid adoption of suPAR testing among the private pay ecosystem - notably the longevity medicine, functional medicine and whole person medicine communities - where there is the most demand for this type of proven test for chronic inflammation. On a personal note, I am grateful for my interactions with Danish culture that have expanded my awareness and satisfied the inner medical anthropologist - I am excited to share suPAR testing in the US and have a reason to visit Denmark more frequently.”